|
|
||||||||
Faculty of Pharmaceutical Sciences and Faculty of Medicine, Kyoto University, Kyoto; Biomedical Imaging Research Center, Fukui Medical School, Fukui, Japan
Correspondence: For correspondence and reprints contact: Yasuhisa Fujibayashi, PhD, D Med Sci, Department of Genetic Biochemistry, Faculty of Pharmaceutical Sciences, Kyoto University, Shimoadachi-cho, Yoshida, Sakyo-ku, Kyoto, 606, Japan.
ABSTRACT
We evaluated the regional distribution of 62Cu-pyruvaldehyde bisi(N4-methylthiosemicarbazone)(62Cu-PTSM), a potential PET perfusion agent, in the rat brain and observed hyperfixation in transient global ischemia in rats. Methods: The distribution of 62Cu-PTSM was examined in comparison with that of 131I-labeled p-iodophenyl-N-isopropylmethanphetamine (131I-IMP) as a reference blood flow marker. Brain uptake of these two tracers was measured in Wistar rats subjected to 30-min four-vessel occlusion followed by recirculation for 10 min, 1 hr or 1, 3 or 5 days. Tracers were injected intravenously into rats 10 min before decapitation. The activities of Complex I and Complex IIII of mitochondria and the concentration of sulfhydryl (SH) groups were also measured. Results: Copper-62-PTSM showed accelerated accumulation in the brain at 1 hr and 1 day after reperfusion when compared with that of 131I-IMP(p < 0.01), and this enhancement was considered to be due to hyperfixation. At these time points, SH concentration was significantly decreased (p < 0.01). On the other hand, the activity of Complex I was not influenced by ischemia/reperfusion, but that of Complex IIII was decreased to 6570% of the control level (p < 0.01). Conclusion: Copper-62-PTSM showed hyperfixation most possibly as a result of increased NADH concentration, caused by disturbed electron transport in mitochondria.
Key Words: hyperfixation cerebral ischemia reperfusion injury copper-62
This article has been cited by other articles:
![]() |
L. Wei, J. Easmon, R. K. Nagi, B. D. Muegge, L. A. Meyer, and J. S. Lewis 64Cu-Azabicyclo[3.2.2]Nonane Thiosemicarbazone Complexes: Radiopharmaceuticals for PET of Topoisomerase II Expression in Tumors J. Nucl. Med., December 1, 2006; 47(12): 2034 - 2041. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Takakura, S. Yaguchi, Y. Kanansugi, K. Kobayashi, R. Okayasu, and Y. Fujibayashi Enhancement of chromosomal aberrations in tumor cells with a non-labeled Cu-PTSM and irradiation with Cu K-shell monochromatic X rays Radiat Prot Dosimetry, December 1, 2006; 122(1-4): 188 - 194. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Lewis, J. M. Connett, J. R. Garbow, T. L. Buettner, Y. Fujibayashi, J. W. Fleshman, and M. J. Welch Copper-64-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for the Prevention of Tumor Growth at Wound Sites following Laparoscopic Surgery: Monitoring Therapy Response with microPET and Magnetic Resonance Imaging Cancer Res., January 1, 2002; 62(2): 445 - 449. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Lewis, R. Laforest, T. L. Buettner, S.-K. Song, Y. Fujibayashi, J. M. Connett, and M. J. Welch Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy PNAS, January 30, 2001; 98(3): 1206 - 1211. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |